Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 214
- Registration Number
- NCT06520397
- Locations
- 🇨🇳
Wei Wang, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 168
- Registration Number
- NCT06425549
- Locations
- 🇺🇸
Ps0021 50196, Northridge, California, United States
🇺🇸Ps0021 50161, Los Angeles, California, United States
🇺🇸Ps0021 50599, Kew Gardens, New York, United States
A Retrospective Observational Study of Ustekinumab Among Bio-naive Participants With Crohn's Disease in China
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06082986
- Locations
- 🇨🇳
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳Sir Run Run Shaw Hospital, affiliated with Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06045754
- Locations
- 🇺🇸
Gastroenterology Research of San Antonio, LLC, San Antonio, Texas, United States
🇺🇸Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸GI Alliance Sun City, Sun City, Arizona, United States
The Application of Transcriptomics in the Treatment of Ulcerative Colitis With Ustekinumab
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Evangelismos Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT05896943
- Locations
- 🇬🇷
Evangelismos Hospital, Athens, Attiki, Greece
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 100
- Registration Number
- NCT05728008
- Locations
- 🇮🇹
Mariangela Allocca, Milano, Italy
Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 50
- Registration Number
- NCT05725876
Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2023-06-13
- Target Recruit Count
- 200
- Registration Number
- NCT05705856
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 240
- Registration Number
- NCT05702879
- Locations
- 🇨🇭
University Hospital Bern Inselspital, Bern, Switzerland
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
- Conditions
- Interventions
- Drug: Squaric Acid Dibutyl EsterOther: Known patch test allergensDevice: MicroneedleDrug: DupilumabDevice: Suction blisteringDrug: AdalimumabProcedure: Skin punch biopsyDrug: UstekinumabDrug: GuselkumabDrug: CanakinumabDrug: SarilumabDrug: Triamcinolone AcetonideDrug: Betamethasone ValerateDrug: Fluticasone Propionate
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- John Harris
- Target Recruit Count
- 45
- Registration Number
- NCT05535738
- Locations
- 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.